Avila Christina, Hoffman Kalyn, Milani-Nejad Nima, Pootrakul Llana
Division of Dermatology, The Ohio State University Department of Internal Medicine, Columbus, OH.
Dermatol Online J. 2020 Jan 15;26(1):13030/qt9g21p2g9.
The combination of dabrafenib and trametinib is an important immunotherapy option for patients with BRAF V600 mutation-positive melanoma. This regimen has been reported to cause cutaneous eruptions. However, hair dysmorphology is not a reported side effect to these or any other medications to date. Herein, we highlight a case of pili multigemini formation in a patient with stage IV melanoma receiving treatment with dabrafenib and trametinib and the corresponding clinical findings.
达拉非尼和曲美替尼联合使用是BRAF V600突变阳性黑色素瘤患者的一种重要免疫治疗选择。据报道，该治疗方案会引起皮肤疹。然而，毛发形态异常至今尚未被报道为这些药物或任何其他药物的副作用。在此，我们重点介绍了一名接受达拉非尼和曲美替尼治疗的IV期黑色素瘤患者出现多毛症的病例及相应的临床发现。
